PURPOSE: Latanoprostene bunod ophthalmic solution 0.024% (LBN) is a nitric oxide-donating prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. This study characterized real-world eye care practitioners’ (ECPs’) experiences and perceptions of LBN in clinical practice.

METHODS: A cross-sectional online survey was administered to ECPs in the United States who had prescribed LBN to ≥10 patients within the prior ≥1 month. Respondents reported on their prescribing patterns, patient characteristics, perceived efficacy, tolerability, and overall satisfaction. Descriptive statistics were used to summarize responses.

RESULTS: Fifty-five ECPs completed the survey (mean [SD] age, 68 ± 15 years). Respondents reported a mean (SD) of 1.42 ± 1.07 years of experience prescribing LBN and a median (IQR) of 1 (1–2) new LBN prescriptions per week, with a median [range] of 29 [17–52] patients currently treated with LBN. Overall, 70% (38/54) of ECPs reported being satisfied or very satisfied with LBN, 65% (35/54) perceived LBN to be more effective than other prostaglandin analogs, and 87% (48/55) indicated they would recommend LBN to a colleague (Table). Perceived efficacy and tolerability were the most frequently cited reasons for prescribing LBN (Figure).

CONCLUSION: In this real-world survey, ECPs reported favorable experiences with LBN, including high levels of satisfaction, perceived efficacy, and willingness to recommend. These findings complement clinical trial data and support the role of LBN in the management of open-angle glaucoma and ocular hypertension.